Journals / The Journal of Pediatric Research / 2017 / Cilt: 4 - Sayı: 4

Endocrinopathies in Turkish Children with Thalassemia Major

Talasemi Majör Tanılı Çocuklarda Endokrin Problemler

Pages
216–219
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, 67.7% of the 62 subjects had height standard deviation score <=-2 and/or at least one endocrinopathy.Conclusion: Growth retardation and endocrine problems are still a serious problem in TM patients, and develop particularly in those older than 7 years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Endocrinopathies are common in patients with thalassemia major (TM) and affect their life quality.
📊
Key Findings & Data:Our aim was to identify the frequency of growth retardation and endocrine complications in these patients.Materials and Methods: Sixty-two patients aged 3-18 years with TM were evaluated retrospectively for height, weight, body mass index (BMI), and pubertal stage.
💡
Conclusion & Impact:Overall, 67.7% of the 62 subjects had height standard deviation score <=-2 and/or at least one endocrinopathy.Conclusion: Growth retardation and endocrine problems are still a serious problem in TM patients, and develop particularly in those older than 7 years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Endocrinopathies are common in patients with thalassemia major (TM) and affect their life quality. Our aim was to identify the frequency of growth retardation and endocrine complications in these patients.Materials and Methods: Sixty-two patients aged 3-18 years with TM were evaluated retrospectively for height, weight, body mass index (BMI), and pubertal stage. Blood tests for endocrine function, and oral glucose tolerance test (OGTT) results were recorded.Results: The mean age of 62 subjects (33 females/29 males) was 10.4±3.9 years. The frequency of <=-2 standard deviation scores was 37.1% for height, 33.9% for weight and 11.3% for BMI. Short stature, being underweight, and low BMI were significantly more prevalent in children over 7 years old (p<0.001). Delayed puberty/hypogonadism was present in 37% of 19 adolescents. Thirteen percent of the subjects had vitamin D deficiency (<10 ng/mL), hyperparathyroidism was observed in 29% of the subjects, while subclinical hypothyroidism (thyroid-stimulating hormone 5-10 IU/mL) was determined in 3 (5.5%) of the 55 subjects. In OGTT, impaired fasting glucose was seen in 7 subjects (14.5%), impaired glucose tolerance in 3 (6.3%), diabetes mellitus in 1 (2.1%), and hypoglycemia at 120-min was observed in 5 subjects (10.4%). Overall, 67.7% of the 62 subjects had height standard deviation score <=-2 and/or at least one endocrinopathy.Conclusion: Growth retardation and endocrine problems are still a serious problem in TM patients, and develop particularly in those older than 7 years. Additionally, attention must be paid to hypoglycemia in these patients as well as diabetes.

Özet

Amaç: Talasemi majörlü (TM) çocuklarda endokrinopatiler halen yaygın bir sorun olup hayat kalitesini önemli bir ölçüde etkilemektedir. Bu çalışmada TM'li çocuklarda büyüme geriliği ve endokrin komplikasyon sıklığının belirlenmesi amaçlanmıştır.Gereç ve Yöntemler: Yaşları 3-18 arasında olan 62 TM hastası boy, kilo, vücut kitle indeksi (VKİ) ve puberte açısından retrospektif olarak değerlendirildi. Hastaların yapılan endokrin testleri ve oral glukoz tolerans testi (OGTT) sonuçları kaydedildi.Bulgular: Altmış iki (33 kız/29 erkek) hastanın ortalama yaşı 10,4±3,9 yıl idi. Hastaların %37,1'inin boyu, %33,9'unun kilosu ve %11,3'ünün VKİ'si <=-2 standart sapma puanı idi. Kısa boy, düşük kilo ve düşük VKİ anlamlı olarak 7 yaş sonrasında görülmekteydi (p<0,001). Gecikmiş puberte/hipogonadizm ise 19 adölesanın %37'sinde saptandı. Hastaların %13'ünde vitamin D eksikliği (<10 ng/mL), %29'unda ise hiperparatiroidi görüldü. Subklinik hipotiroidi (tiroid stimüle edici hormon 5-10 IU/mL) ise 55 hastanın 3'ünde (%5,5) mevcuttu. OGTT sonuçlarına göre, bozulmuş açlık glukozu 7 (%14,5), bozulmuş glukoz toleransı 3 (%6,3), diabetes mellitus 1 (%2,1) ve 2. saatte hipoglisemi 5 (%10,4) hastada saptandı. Toplamda 62 hastanın %67,7'sinde boy kısalığı ve/veya en az bir endokrinopati mevcuttu.Sonuç: Büyüme geriliği ve endokrin problemler halen ciddi bir sorun olup özellikle 7 yaş sonrasında ortaya çıkmaktadır. Ayrıca TM'li hastalarda diyabet kadar hipoglisemi açısından da dikkatli olunmalıdır.

🔖

Cite This Article

HALİLOĞLU, B., KİNTRUP, G. T., TAYFUN, F. (2017). Endocrinopathies in Turkish Children with Thalassemia Major. The Journal of Pediatric Research, Cilt: 4 - Sayı: 4, 216–219. https://ajindex.com/articles/362787

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227-31
  2. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double-blind trial of the effect of combined therapy with Deferoxamine and Deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84
  3. Aydinok Y, Darcan S, Polat A, et al. Endocrine complications in patients with beta-thalassemia major. J Trop Pediatr 2002;48:50- 4
  4. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassemia major. Br J Haematol 2010;148:466-75
  5. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusiondependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Molec Dis 2011;47:33- 40
  6. Platis O, Anagnostopoulos G, Farmaki K, Posantzis M, Gotsis E, Tolis G. Glucose metabolism disorders improvement in patients with thalassemia major after 24-36 months of intensive chelation therapy. Pediatr Endocrinol Rev 2004;2(Suppl 2):279- 81
  7. Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium: Type 2 diabetes in the child and adolescent. Pediatr Diabetes 2015;16:392
  8. Chatterjee R, Bajoria R. Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann N Y Acad Sci 2010;1202:100-14
  9. Isik P, Yarali N, Tavil B, et al. Endocrinopathies in Turkish children with Beta thalassemia major: results from a single center study. Pediatr Hematol Oncol 2014;31:607-15
  10. Theodoridis C, Ladis V, Papatheodorou A, et al. Growth and management of short stature in thalassemia major. J Pediatr Endocrinol Metab 1998;11(Suppl 3):835-44
  11. Roth C, Pekrun A, Bartz M, et al. Short stature and failure of pubertal development in thalassemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997;156:777-83
  12. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta- thalassemia major in a developing country. J Pediatr Endocrinol Metab 2000;13:651-6
  13. Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sc